Ulcerative Colitis Clinical Trial
Official title:
The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis
The purpose of this study is to determine if home automated telemanagement improves bowel symptoms, quality of life, compliance with medications, and health care utilization compared to best available care in patients with ulcerative colitis.
Ulcerative colitis (UC) is a common inflammatory condition of the bowels that results in
bloody diarrhea, abdominal pain, and lack of control of bowel movements. UC is a chronic
medical condition that causes frequent episodes of symptoms ("flares") followed by
symptom-free intervals. Although drugs are available to treat the symptoms, there are
obstacles to successful treatment. Because patients need to take medications continuously to
avoid flares, compliance with drugs can difficult. Monitoring the symptoms of UC is also
challenging, because flares are sporadic and often do not occur at the time of routine office
visits. This can result in treatment delays. Although the drugs used to treat colitis are
effective, they have side effects which can decrease compliance and quality of life.
Patient's knowledge of the disease can also be poor, which can affect many aspects of care.
Telemanagement systems are telemedicine systems that are designed to (1) assist physicians in
monitoring their patients, (2) assist physicians in following current guidelines, (3) help
patients follow self-care plans, and (4) deliver educational facts to patients. Telemedicine
systems have been used in diseases similar to UC and have improved outcomes. We designed a
telemanagement system specifically for patients with inflammatory bowel disease (IBD HAT) and
found that IBD HAT was easy to use, was accepted by patients, and improved various aspects of
patient care including patient knowledge, quality of life, and bowel symptoms.
The purpose of the study is to determine if a home telemanagement system for patients with UC
(UC HAT) improves clinical outcomes compared to routine care. Patients with UC will be
identified from the University of Maryland IBD program and the gastroenterology clinic of the
VA Maryland Health Care System, Baltimore. A computer program will assign interested patients
by chance to either the UC HAT or the routine care group. Patients in the UC HAT group will
be asked to complete self-testing each week at home using the system. The home-unit consists
of a laptop computer and electronic weight scale. After turning on the computer, patients
answer questions about their bowel symptoms, medication side effects, and compliance with
medications. The home-unit then prompts subjects to measure their weight on the scale.
Subjects then receive an educational "tip of the day". The following session, subjects answer
an educational question that relates to the tip. After self-testing is completed, the results
are transmitted via a phone line to our secure server. The results are made available
immediately for review on the physician's web portal. Based on the responses to the symptom
diary, side effect questions, medical compliance, and body weight, electronic alerts and
action plans can be generated. An alert is sent electronically to the study coordinator, who
then reviews the information and discusses the findings with the principal investigator and
the patient's medical provider. Changes in patient management can be made if appropriate. An
action plan is created for each patient at the first visit and contains a list of tasks for
patients to start immediately after self-testing if certain criteria are met. Patients still
undergo regularly scheduled clinical visits as prescribed by their medical provider.
Patients assigned to the routine care group will undergo scheduled follow up clinical visits,
telephone follow up, and receive educational fact sheets about their disease. This is
considered routine care at our centers. All patients will undergo research visits every 3
months for one year. Patients will complete a series of questionnaires at each visit that
measure the patient's disease activity, quality of life, IBD knowledge, medical compliance,
and other parameters. Emergency room visits and hospitalizations will also be measured. A
blood draw is required at each study visit.
We think that UC HAT will improve the monitoring of bowel symptoms and medication side
effects and improve medical compliance. These improvements should result in decreased bowel
symptoms, improved quality of life, and decreased urgent care visits and hospitalizations. If
UC HAT is effective, the system could be used in the IBD community to improve clinical care
or be used in patients with limited access to health care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |